| 38.62 -0.86 (-2.18%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 46.49 |
1-year : | 48.15 |
| Resists | First : | 39.8 |
Second : | 41.22 |
| Pivot price | 39.3 |
|||
| Supports | First : | 37.5 |
Second : | 31.2 |
| MAs | MA(5) : | 39.13 |
MA(20) : | 39.46 |
| MA(100) : | 31.46  |
MA(250) : | 25.6 |
|
| MACD | MACD : | 0.7 |
Signal : | 1 |
| %K %D | K(14,3) : | 37.2 |
D(3) : | 40.7 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 41.22 | Low : | 14.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMVT ] has closed above bottom band by 18.0%. Bollinger Bands are 62.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 39.36 - 39.55 | 39.55 - 39.74 |
| Low: | 37.4 - 37.64 | 37.64 - 37.87 |
| Close: | 38.17 - 38.56 | 38.56 - 38.93 |
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Tue, 28 Jul 2026
Immunovant, Inc. Revenue Breakdown – NASDAQ:IMVT - TradingView
Mon, 27 Jul 2026
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy - Seeking Alpha
Thu, 23 Jul 2026
Roivant to Host Immunovant’s Aug. 6 Business Update Webcast - Stock Titan
Wed, 22 Jul 2026
Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed - Quiver Quantitative
Wed, 22 Jul 2026
Immunovant, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
Fri, 12 Jun 2026
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 205 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 56 (%) |
| Held by Institutions | 54 (%) |
| Shares Short | 17,760 (K) |
| Shares Short P.Month | 19,340 (K) |
| EPS | -2.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.5 % |
| Return on Equity (ttm) | -64.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -407 (M) |
| Levered Free Cash Flow | -234 (M) |
| PE Ratio | -13.95 |
| PEG Ratio | 0 |
| Price to Book value | 9.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|